| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-03-15 | Lonza (Switzerland) Enobia (Canada) | ENB-0040 (asfotase alfa) | hypophosphatasia | manufacturing |
Bone diseases - Genetic diseases - Metabolic diseases | Production agreement |
| 2011-03-15 | instrAction (Germany) Protagen (Germany) | instrAction ® Phases for downstream processing of biotherapeutics. | collaboration |
Collaboration agreement | ||
| 2011-03-15 | KINAXO Biotechnologies (Germany) Takeda Pharmaceutical (Japan) | Phosphoscout | services |
Services contract | ||
| 2011-03-14 | Chroma Therapeutics (UK) Cell Therapeutics (USA) | tosedostat | relapsed or refractory acute myeloid leukemia - blood related cancers | co-development |
Cancer - Oncology | Licensing agreement |
| 2011-03-10 | MediGene (Germany) Will-Pharma (Belgium) | Veregen® ointment (made from the extract of green tea leaves - catechins) | External genital warts | commercialisation |
Gynecology - Infectious diseases | Commercialisation agreement |
| 2011-03-10 | Cancer Research Technology (UK) The Institute of Cancer Research (ICR) (UK) ZoBio BV (the Netherlands) | drugs to block a DNA repair target which may play a role in cancer cell survival | cancer | R&D |
Cancer Oncology | R&D agreement |
| 2011-03-10 | Pepscan Therapeutics (The Netherlands) Crucell (J&J - USA) | novel vaccines | R&D |
Infectious diseases | R&D agreement | |
| 2011-03-09 | Evotec (Germany) Harvard University (USA) Howard Hughes Medical Institute (USA) | orally available small molecule therapies that trigger or support beta cell replication. | Diabetes | R&D |
Metabolic diseases | R&D agreement |
| 2011-03-08 | ProteoNic (The Netherlands) Oxford Expression Technologies (UK) | protein expression products and systems | collaboration |
Collaboration agreement | ||
| 2011-03-08 | Sanofi-Aventis (France) WHO | donation including medicines, as well as funding for professional training, disease awareness campaigns, logistics and infrastructure | sleeping sickness (Trypanosomiasis) and other neglected tropical diseases | collaboration |
Tropical diseases Infectious diseases | Collaboration agreement |
| 2011-03-08 | Genethon (France) Wake Forest University School of Medicine (USA) | gene therapy for myotubular myopathy | myotubular myopathy | collaboration |
Rare diseases - Neuromuscular diseases | Collaboration agreement |
| 2011-03-07 | AstraZeneca (UK) Galderma (Switzerland) | new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis | dermatological conditions including psoriasis, acne and atopic dermatitis | R&D |
Autoimmune diseases - Dermatological diseases | R&D agreement |
| 2011-03-03 | Bayer HealthCare(Germany) WHO (World Health Organization) | Lampit® tablets (nifurtimox) | Chagas disease | collaboration |
Infectious diseases - Parasitic diseases | Collaboration agreement |
| 2011-03-03 | NeuroVive Pharmaceutical (Sweden) European Brain Injury Consortium (EBIC - network of European neurological research and medical units highly experienced in the care of patients with brain injuries) | NeuroSTAT® | neuroprotection in patients with traumatic brain injury | clinical collaboration |
CNS diseases - Traumatology | Clinical research agreement |
| 2011-03-01 | Philogen (Italy) Pfizer (USA - NY) | cancer targets | cancer | R&D |
Cancer - Oncology | R&D agreement |
| 2011-02-28 | Hemarina (France) U.S. Naval Medical Research Center (USA) | HEMARINA-M101 (HEMOXYcarrier®) | traumatic brain injury | R&D |
Traumatology - CNS diseases | R&D agreement |
| 2011-02-28 | Novalix(France)Janssen-Cilag(France) | R&D |
R&D agreement | |||
| 2011-02-28 | Epigenomics (Germany) Qiagen (The Netherlands) | colorectal cancer blood test based on Epigenomics’ proprietary biomarker mSEPT9 and certain DNA methylation analysis technologies | colorectal cancer | development commercialisation |
Cancer - Oncology | Development agreement |
| 2011-02-28 | Affiris (Austria) GSK (UK) | Alzheimer's disease | development |
Neurodegenerative diseases | Development agreement | |
| 2011-02-25 | Ipsen (France) bioMérieux (France) | companion diagnostic tests in the prevention and treatment of prostateand breast cancers, neuro-endocrine tumors (NETs) and pituitary tumors | prostate cancer, breast cancer, neuro-endocrine tumors, pituitary tumors | R&D |
Cancer - Oncology | R&D agreement |
